Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704219 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT04704219 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 160 participants.
The verdict
NCT04704219, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2025-10-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04704219
The ClinicalTrials.gov registry entry for NCT04704219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04704219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04704219 about?
NCT04704219 is a clinical study titled "Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)". This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.
What is the current status of trial NCT04704219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2021-02-23. Estimated completion is 2025-10-21.
What interventions are being tested in trial NCT04704219?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04704219?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.